Aeterna Zentaris (AEZS) Affirms Fundamental Strength of Business and Prospects
Tweet Send to a Friend
Aeterna Zentaris (NASDAQ: AEZS) affirms that its business and prospects remain fundamentally strong and highlights the following developments:Zoptrex™ (zoptarelin doxorubicin) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE